

114. A T cell activating bispecific antigen binding molecule produced by the method of claim 113.
115. A pharmaceutical composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 and a pharmaceutically acceptable carrier.
- 5 116. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 or the pharmaceutical composition of claim 115 for use as a medicament.
117. The T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 or the pharmaceutical composition of claim 115 for use in the treatment of a disease in an individual in need thereof.
- 10 118. The T cell activating bispecific antigen binding molecule or pharmaceutical composition of claim 117, wherein the disease is cancer.
119. Use of the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 for the manufacture of a medicament for the treatment of a disease in an individual in need thereof.
- 15 120. A method of treating a disease in an individual, comprising administering to said individual a therapeutically effective amount of a composition comprising the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 in a pharmaceutically acceptable form.
121. The use of claim 119 or the method of claim 120, wherein said disease is cancer.
- 20 122. A method for inducing lysis of a FolR1⁺ target cell, comprising contacting a target cell with the T cell activating bispecific antigen binding molecule of any one of claims 1 to 99 in the presence of a CD3⁺ T cell.